Forecast

There is no analyst data available for this company.

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last quarter, Nanocarrier had revenue of €236.73k and net profit of -€2.73m

(EUR) September 2026
YoY
Revenue 236.73k 23.10%
Gross profit 204.79k 42.72%
Net profit -2.73m 97.82%
EBITDA -2.36m 72.08%

Fundamentals

Metric Value
Market capitalization
€34.02m
Number of shares
91.05m
52-week high/low
€1.12 - €0.36
Dividends No
Beta
0.41
P/E ratio
-4.14
PEG ratio
0.12
P/B ratio
1.70
P/S ratio
28.00

Company profile

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.

Name
Nanocarrier
CEO
Shiro Akinaga
Headquarters Minato,
Japan
Website
IPO
05/03/2008
Employees 23

Ticker symbols

Exchange Symbol
Japan Exchange Group
4571.T
Frankfurt
3NQ.F
München
3NQ.MU
Düsseldorf
3NQ.DU
🍪

Parqet  uses cookies. Learn more